5 Cheap Healthcare Stocks to Buy in 2023
Three of the 943 hedge funds part of Insider Monkey's database had bought Molecular Partners AG (NASDAQ:MOLN)'s shares during Q4 2022.
Molecular Partners Ag (MOLN)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 443,221 | $2,136,325 | 0.06% | |
| 2. | Suvretta Capital Management Aaron Cowen | 400,000 | $2,034,840 | 0.06% | |
| 3. | Tang Capital Management Kevin C. Tang | 0 | $0 | 0% |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 12,618 | $50,220 | 0% | |
| 2. | 367 | $1,534 | 0% | |
| 3. | 269 | $1,070 | 0% | |
| 4. | 16 | $64 | 0% | |
| 5. | 1 | $4 | 0% |
News See All
Molecular Partners AG (NASDAQ:MOLN) Q4 2022 Earnings Call Transcript
Operator: Good day and welcome to the Molecular Partners Publication of Full Year Results 2022 Conference Call. Please note this event is being recorded.